2025-01-12 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Review

**1. Performance Comparison & Divergence:**

UnitedHealth Group Inc. (UNH) is a diversified healthcare company providing health benefits, health services, and data and technology services.  The cumulative return of UNH is 140.17%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 112.20%. The difference is 28.0%, placing it in the 90th percentile of historical relative performance (relative divergence of 23.0) against the S&P 500 based on provided data.  This indicates UNH's strong historical outperformance.


**2. Recent Price Movement:**

* **Closing Price:** $520.69
* **5-Day Moving Average:** $517.23
* **20-Day Moving Average:** $509.04
* **60-Day Moving Average:** $557.54

The price is slightly above the 5-day moving average, suggesting recent upward momentum.  However, it's below both the 20-day and 60-day moving averages, indicating a potential short-term pullback from higher levels.


**3. Technical Indicators and Expected Return:**

* **RSI:** 66.56 (Slightly above neutral, suggesting neither overbought nor oversold conditions)
* **PPO:** 0.84 (Positive, indicating bullish momentum)
* **Recent Relative Divergence:** +6.3 (Short-term upward trend)
* **Expected Return (2+ years):** 265.2% (Significantly higher than S&P 500, implying substantial potential outperformance given the company's historical performance).  This high expected return warrants scrutiny; it is crucial to examine the underlying assumptions and potential risks involved.

The current price ($520.69) is relatively close to the 20-day and 60-day moving averages which are considered signals of a current price correction.  There's no evidence of a sharp price surge or drop at present but a correction is possible.


**4. Recent Earnings Analysis:**

| Date       | EPS     | Revenue         |
|------------|---------|-----------------|
| 2024-11-04 | 6.56    | $100.82 B       |
| 2024-08-09 | 4.58    | $98.86 B       |
| 2024-05-09 | -1.53   | $99.80 B       |
| 2023-11-06 | 6.31    | $92.36 B       |
| 2024-11-04 | 6.31    | $92.36 B       |

There appears to be a duplicate entry for November 2024.  Excluding the duplicate, revenue shows steady growth, with EPS fluctuating. The significant negative EPS in Q2 2024 warrants further investigation to understand the contributing factors.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue      | Profit Margin |
|-------------|--------------|---------------|
| 2024-09-30 | $99.18B      | 21.56%        |
| 2024-06-30 | $97.86B      | 21.52%        |
| 2024-03-31 | $98.78B      | 22.26%        |
| 2023-12-31 | $93.25B      | 22.33%        |
| 2023-09-30 | $91.36B      | 24.51%        |

Revenue shows consistent growth, although profit margins have slightly decreased recently.

**Capital and Profitability:**

| Quarter     | Equity       | ROE           |
|-------------|--------------|---------------|
| 2024-09-30 | $94.53B      | 6.41%         |
| 2024-06-30 | $89.36B      | 4.72%         |
| 2024-03-31 | $86.69B      | -1.63%        |
| 2023-12-31 | $88.76B      | 6.15%         |
| 2023-09-30 | $84.49B      | 6.91%         |

Equity is increasing, but ROE shows some volatility, with a significant negative value in Q1 2024. This negative ROE requires further analysis.


**7. Overall Analysis:**

UNH has historically outperformed the S&P 500, showing strong cumulative returns.  Recent price action suggests a potential short-term pullback. Technical indicators present a mixed picture, with positive momentum but RSI suggesting neither overbought nor oversold conditions.  While the projected long-term return is very high, the accuracy depends heavily on the model used to generate this value and its assumptions.  The recent earnings report shows mixed results with revenue growth but fluctuating EPS and even negative EPS in one quarter. Financial information indicates stable revenue growth but some volatility in profit margins and ROE.  Thorough due diligence is needed given the significant projected return which is a primary focus for future analysis.  Further investigation into the Q2 2024 negative EPS and ROE is crucial for a complete assessment of UNH's financial health and future prospects.

**8. Disclaimer:** This analysis is based on the provided data and is for informational purposes only.  It is not financial advice.  Investing in the stock market involves risk, and you should conduct your own thorough research and consult with a financial advisor before making any investment decisions.
